Bio Expo Online
08.12.2005 KineMed Presents Innovative New Assays for Measurement of in vivo Cartilage Dynamics at the World Congress on Osteoarthritis:
EMERYVILLE, Calif., Dec. 8, 2005 /PRNewswire/ — KineMed, Inc., a platform-based indications discovery and development drug company, announced today that two posters detailing results from a new product program will be presented at the World Congress on Osteoarthritis meeting to be held in Boston, MA from December 08, 2005-11th, 2005.
The presentation […]
07.12.2005 Humanetics and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Sign Exclusive License for Oral Agent to Protect and Strengthen the Immune System Against Radiation Exposure in Terrorist Attack:
MINNEAPOLIS–(BUSINESS WIRE)–Dec 8, 2005 - Humanetics Corporation today announced the signing of a worldwide exclusive licensing agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., (HJF) to further develop an oral agent, BIO300, for strengthening and protecting the immune system against radiation exposure.
BIO300 was jointly developed by researchers at the […]
06.12.2005 Xceleron and Servier Sign Collaborative Agreement to Accelerate Drug Development Using Microdosing:
YORK, Scotland, December 7, 2005 - Xceleron, the bioanalytical CRO who has pioneered human Phase 0 microdose studies and Servier, a French pharma company, announce today that they have signed a twelve-month rolling Collaborative Agreement. The Agreement covers the provision by Xceleron of accelerator mass spectrometry (AMS) services to assist Servier in taking candidate drugs […]
05.12.2005 Evotec Reaches First Milestone and Receives Success Payment in Alzheimer’s Disease Collaboration With Takeda:
HAMBURG, Germany, December 06, 2005 /PRNewswire-FirstCall/ — Evotec AG announced today that the first milestone has been achieved in its four-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”).
Evotec has granted Takeda exclusive rights in a novel target in Alzheimer’s disease based on successful target identification and validation work triggering a milestone […]
02.12.2005 Spectrum Pharmaceuticals Announces Achievement of Target Enrollment in Satraplatin Phase 3 Registrational Trial (SPARC) for Second-Line Chemotherapy of Hormone Refractory Prostate Cancer:
IRVINE, Calif., Dec. 5 /PRNewswire-FirstCall/ — Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) today announced the achievement of target enrollment in the Phase 3 registrational trial of its lead drug candidate satraplatin, the only orally bioavailable platinum-based compound in advanced clinical development. The SPARC trial (Satraplatin and Prednisone Against Refractory Cancer) managed by the Company’s co-development partner, […]
new | february 2007 | january 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004